Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-subQ: SC Rilvegostomig in Advanced Solid Tumors
NCT07161414Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of rilvegostomig in solid tumor (3 arms), sponsored by AstraZeneca. Primary endpoint: Area under the Concentration-time Curve During One Dosing Interval. Started Nov 2025; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07161414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07161414.